Characteristics of newly diagnosed patients with T-ALL (n=188)
| Characteristics | Pediatric (n=83) | Adult (n=105) |
| Age (in years) | ||
| Median | 9 years | 21 years |
| Range | 1–15 years | 15–53 years |
| Male:female ratio | 4.2 | 9.5 |
| WBC counts | ||
| Median | 26.3×103/µL | 23.4×103/µL |
| Range | 0.46–626×103/µL | 0.26–506×103/µL |
| Sample type | ||
| PB | 44.60% | 40.00% |
| BM | 55.40% | 60.00% |
| Blast % at diagnosis | ||
| Median | 81.00% | 82.00% |
| Range | 25%–98% | 25%–97% |
| Morphological (BM) remission status | ||
| Available in | n=80 | n=72 |
| Not in remission (refractory) | 10/80 (12.5%) | 14/72 (19.4%) |
| MRD positive status | ||
| EOI-MRD: available in | n=80 | n=72 |
| EOI-MRD: positive | 45/80 (56.3%) | 45/72 (62.5%) |
| EOI-MRD levels | ||
| Median | 1.60% | 0.55% |
| Range | 0.01% to 66.3% | 0.01% to 72.6% |
| EOC-MRD: available in | n=52 | n=44 |
| EOC-MRD: positive | 15/52 (21.1%) | 19/44 (43.2%) |
| EOC-MRD levels | ||
| Median | 6.70% | 0.09% |
| Range | 0.01% to 30.9% | 0.01% to 2.5% |
BM, bone marrow; EOC, end of consolidation; EOI, end of induction; MRD, minimal residual disease; PB, peripheral blood; T-ALL, T-cell acute lymphoblastic leukemia; WBC, white blood cell.